Hamidreza Khajeha
Biographic Data
| ID | 7763813 |
|---|---|
| NAME | Hamidreza Khajeha |
| GIVEN NAMES | Hamidreza |
| FAMILY NAME | Khajeha |
| SIGNATURE | KHAJEHA H |
| AFFILIATIONS | Shahroud University of Medical Sciences |
| ORCID | 0000-0003-2149-927X |
| VERIFIED | Yes |
| TOTAL WORKS | 3 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 3 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2022 |
| LATEST PUBLICATION YEAR | 2025 |
| H-INDEX | 0 |
Safety of sinopharm Covid-19 vaccine in children and adolescents aged 5 to 18 years
Sinopharm is a safe and well-tolerated vaccine option for children and adolescents and can be recommended for this population
A prospective cohort study protocol
With the planned study we will provide a valid epidemiological evidence to improve the understanding of the safety of the booster dose of the AstraZeneca and to better evaluate the effectiveness of public health interventions. This could help policy makers in managing the COVID-19 pandemic according to scientific evidence
Study protocol
The results of this study will be published in different articles. A live dashboard is also available for managers and policymakers. All data will be available on reasonable requests from the corresponding author.The use of the good and comprehensive guidelines provided by WHO, along with the accurate implementation of the protocol and continuous monitoring of the staff performance are the main strengths of this study which may be very useful for…
No prominent works on this page.
Study protocol
The results of this study will be published in different articles. A live dashboard is also available for managers and policymakers. All data will be available on reasonable requests from the corresponding author.The use of the good and comprehensive guidelines provided by WHO, along with the accurate implementation of the protocol and continuous monitoring of the staff performance are the main strengths of this study which may be very useful for…
A prospective cohort study protocol
With the planned study we will provide a valid epidemiological evidence to improve the understanding of the safety of the booster dose of the AstraZeneca and to better evaluate the effectiveness of public health interventions. This could help policy makers in managing the COVID-19 pandemic according to scientific evidence
Safety of sinopharm Covid-19 vaccine in children and adolescents aged 5 to 18 years
Sinopharm is a safe and well-tolerated vaccine option for children and adolescents and can be recommended for this population
Cohort (3 works) · SARS-CoV-2 and COVID-19 Research (3 works) · Vaccine Coverage and Hesitancy (3 works) · Biostatistics (2 works) · Cohort study (2 works) · Environmental health (2 works) · Epidemiology (2 works) · Immunology (2 works) · Internal Medicine (2 works) · Medicine (2 works)